Last reviewed · How we verify

Bio Sidus SA — Portfolio Competitive Intelligence Brief

Bio Sidus SA pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Teriparatide (rDNA origin) Teriparatide (rDNA origin) marketed Parathyroid hormone analog PTH1 receptor (PTHR1) Endocrinology / Bone Metabolism
Erythropoietin alfa Erythropoietin alfa phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Amgen · 1 shared drug class
  3. Anemia Working Group Romania · 1 shared drug class
  4. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  5. Australian and New Zealand Intensive Care Research Centre · 1 shared drug class
  6. Barts & The London NHS Trust · 1 shared drug class
  7. Biocad · 1 shared drug class
  8. Affymax · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Bio Sidus SA:

Cite this brief

Drug Landscape (2026). Bio Sidus SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bio-sidus-sa. Accessed 2026-05-14.

Related